… Our leading intellectual property portfolio protects our Axiomer ® ADAR-mediated RNA editing platform technology and … patent protection related to its RNA editing platform, Axiomer ® , including more than 11 published patent families, … its IP estate around ADAR-mediated RNA editing. About Axiomer ® ProQR is pioneering a next-generation RNA base …
… transformative RNA therapies based on its proprietary Axiomer ® RNA editing technology platform, today reported its … pleased with the continued progress in advancing our Axiomer ® RNA editing platform and believe we’re only at the … In November ProQR announced its IP estate surrounding its Axiomer ® RNA editing platform was further strengthened by: …
… An innovative biotech company advancing our proprietary Axiomer RNA-editing platform technology. We are ProQR We are … and common diseases. We focus on advancing our proprietary Axiomer™ RNA-editing platform technology. ProQR has offices …
… the event, the Company will showcase its proprietary Axiomer ® RNA-editing technology platform, announce initial … and mentored over 50 Ph.D. and M.S. degree students. About Axiomer ® ProQR is pioneering a next-generation RNA base editing technology called Axiomer ® , which could potentially yield a new class of …
… treatments for people with rare genetic diseases. Axiomer RNA base editing At ProQR we invented the Axiomer™ technology that enables single base editing to …
At ProQR, we are dedicated to improving the lives of patients and families affected by rare and common disorders using Axiomer, our innovative RNA editing platform technology.
At our offices in Leiden we are advancing our proprietary Axiomer RNA-editing platform technology. Our ProQRians, representing over 30 nationalities, are passionate and driven to change the lives of patients and their loved ones.
Axiomer™ ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810 targeting NTCP for Cholestatic diseases Company expects up to four clinical data readouts in 2025 and 2026 across multi
